Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de Elafibranor em Pacientes com Colangite Biliar Primária (PBC) (ELATIVE)

20 de outubro de 2026 atualizado por: Ipsen

Um estudo duplo-cego, randomizado, controlado por placebo e extensão aberta de longo prazo para avaliar a eficácia e a segurança de Elafibranor 80 mg em pacientes com colangite biliar primária com resposta inadequada ou intolerância ao ácido ursodesoxicólico

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease).

PBC is a slowly progressive disease characterized by damage of the bile ducts in the liver, leading to a buildup of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done.

The main aim of this study is to determine if elafibranor (the study drug) is better than placebo (a dummy treatment) at decreasing the levels of a specific blood test (alkaline phosphatase) that provides information about participant's disease. This study will also evaluate the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itchy skin (pruritus) and tiredness (fatigue).

This study has two main parts:

Part 1 will compare a daily dose of elafibranor to a daily dose of placebo and will last between a minimum of one year and a maximum of two years.

Part 2, all participants will receive elafibranor for a period of up to 5 years or until the total treatment duration (part 1 and part 2) reaches 6 years, whichever occurs first.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

161

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Alemanha
      • Berlin, Alemanha, 10825
        • Gastro - Sudien
      • Berlin, Alemanha, 13353
        • Charite - Universitätsmedizin Berlin- CVK - Medizinische Klinik
      • Frankfurt, Alemanha, 60590
        • Universitätsklinikum Frankfurt
      • Hanover, Alemanha, 30625
        • Medizinische Hochschule Hannover
      • Kiel, Alemanha, 24146
        • Center for Gastroenterology and Hepatology (GHZ) Kiel
      • Leipzig, Alemanha, 04103
        • EUGASTRO GmbH
      • Mainz, Alemanha, 55131
        • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
  • Argentina
    • Buenos Aires
      • CABA, Buenos Aires, Argentina, 1199
        • Hospital Italiano de Buenos Aires
      • CABA, Buenos Aires, Argentina, C1280AEB
        • Hospital Británico de Buenos Aires
      • Caba, Buenos Aires, Argentina, C1118AAT
        • Hospital Alemán
      • La Plata, Buenos Aires, Argentina, 1900
        • Hospital Italiano de La Plata
    • Mendoza Province
      • Godoy Cruz, Mendoza Province, Argentina, 5547
        • Hospital Espanol De Mendoza
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2002KDS
        • Hospital Provincial del Centenario
  • Brasil
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
        • Hospital de Clínicas de Porto Alegre
    • São Paulo
      • São Paulo, São Paulo, Brasil, 05403-000
        • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo-HCFMUSP
  • Bélgica
      • Brussels, Bélgica, 1070
        • Hôpital Erasme
      • Edegem, Bélgica, 2650
        • Antwerp University Hospital
      • Ghent, Bélgica, 9000
        • Universitair Ziekenhuis Gent
      • Leuven, Bélgica, 3000
        • University Hospital Leuven
  • Canadá
      • Montreal, Canadá, H2X 0A9
        • Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)
    • Alberta
      • Calgary, Alberta, Canadá, T2N 4Z6
        • University of Calgary Liver Unit - Heritage Medical Research Clinic (HMRC)
    • British Columbia
      • Vancouver, British Columbia, Canadá, V5Z IM9
        • Gordon and Leslie Diamond Health Care Centre, Division of Gastroenterology
    • Manitoba
      • Winnipeg, Manitoba, Canadá, R3E 3P4
        • Shared Health Inc.-Operating as Health Sciences Centre-John Buhler Research Centre
  • Chile
      • Santiago, Chile, 7550000
        • Clínica Universidad de los Andes
    • Coquimbo Region
      • La Serena, Coquimbo Region, Chile, 1700000
        • Hospital de La Serena
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 8330034
        • Centro de Investigacion Clinica Universidad Catolica CICUC
      • Santiago, Santiago Metropolitan, Chile, 8320000
        • Hospital Clínico Universidad de Chile
    • Valparaiso
      • Viña del Mar, Valparaiso, Chile, 2540364
        • Centro de Investigaciones Clinicas (CIC)
  • Espanha
      • Barcelona, Espanha, 08036
        • Hospital Clinic de Barcelona
      • Barcelona, Espanha, 08035
        • Hospital Universitario Vall d'Hebron
      • Madrid, Espanha, 28046
        • Hospital Universitario La Paz
      • Madrid, Espanha, 28007
        • Hospital General Universitario Gregorio Marañón
      • Madrid, Espanha, C.P 28222
        • Hospital Universitario Puerta de Hierro -Madrid
      • Pontevedra, Espanha, 36071
        • Complexo Hospitalario Universitario de Pontevedra
      • San Sebastián, Espanha, 20014
        • Hospital Universitario Donostia
      • Santander, Espanha, 39010
        • Hospital Universitario Marqués de Valdecilla
      • Seville, Espanha, 41013
        • Hospital Universitario Virgen del Rocio
  • Estados Unidos
    • Arizona
      • Chandler, Arizona, Estados Unidos, 85224
        • The Institute for Liver Health
    • California
      • Los Angeles, California, Estados Unidos, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, Estados Unidos, 90036
        • Ruane Clinical Research Group Inc.
      • Los Angeles, California, Estados Unidos, 90033
        • Keck Medical Center of USC
      • Sacramento, California, Estados Unidos, 95817
        • University of California, Davis Medical Center
      • San Francisco, California, Estados Unidos, 94109
        • California Pacific Medical Center - Sutter Pacific Medical Foundation
    • Colorado
      • Aurora, Colorado, Estados Unidos, 840045
        • University of Colorado Denver and Hospital
      • Englewood, Colorado, Estados Unidos, 80113
        • South Denver Gastroenterology, P.C.
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510
        • Yale School of Medicine, Digestive Diseases
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32256
        • Encore Borland-Groover Clinical Research
      • Miami, Florida, Estados Unidos, 33136
        • Schiff Center for Liver Diseases/University of Miami
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30309
        • Digestive Healthcare of Georgia
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • University of Kansas Medical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Estados Unidos, 02215
        • Beth Israel Deaconess Medical Center (BIDMC)
    • Michigan
      • Novi, Michigan, Estados Unidos, 48377
        • Henry Ford Health System
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63104
        • Saint Louis University
    • New York
      • New Hyde Park, New York, Estados Unidos, 11042-11114
        • UPMC Center for Liver Diseases
      • New York, New York, Estados Unidos, 10016
        • NYU Langone Health / NYU Grossman School of Medicine
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center - Center for Liver Disease and Transplantation
      • New York, New York, Estados Unidos, 10065
        • The New York-Presbyterian Hospital, David H. Koch Center
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University Medical Center
      • Huntersville, North Carolina, Estados Unidos, 28078
        • Carolinas Centre for Liver disease/ Atrium Health
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45249
        • Consultants for Clinical Research
      • Cleveland, Ohio, Estados Unidos, 44106
        • University Hospitals Cleveland Medical Center
      • Columbus, Ohio, Estados Unidos, 43210-1240
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Investigational Drug Service Pharmacy Penn State Milton S. Hershey Medical Center
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Thomas Jefferson University
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Medical University of South Carolina- College of Medicine
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Vanderbilt Digestive Disease Center
    • Texas
      • Arlington, Texas, Estados Unidos, 76012
        • Texas Clinical Research Institute, LLC
      • Dallas, Texas, Estados Unidos, 75203
        • The Liver Institute at Methodist Dallas Medical Center
      • Dallas, Texas, Estados Unidos, 75234
        • Liver Center of Texas, PLLC
      • Dallas, Texas, Estados Unidos, 75390-8575
        • The University of Texas Southwestern Medical Center-IDS Aston Pharmacy
      • Fort Worth, Texas, Estados Unidos, 76104
        • Texas Digestive Disease Consultants dba GI Alliance
      • Houston, Texas, Estados Unidos, 77030
        • Liver Associates of Texas, P.A.
      • Houston, Texas, Estados Unidos, 77030
        • St. Luke's Health-Baylor St Luke's Medical center - Advanced Liver Therapies Research
      • San Antonio, Texas, Estados Unidos, 78215
        • American Research Corporation
      • Victoria, Texas, Estados Unidos, 77904
        • Gastro health & Nutrition-Victoria
    • Utah
      • Murray, Utah, Estados Unidos, 84107
        • Intermountain Medical Center - Transplant Services
      • Salt Lake City, Utah, Estados Unidos, 84132
        • University of Utah Hospital-Division of Gastroenterology, Hepatology, and Nutrition
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • University of Virginia Medical Center
      • Newport News, Virginia, Estados Unidos, 23602
        • Maryview Hospital Inc, Bon Secours Liver Institute of Hampton Roads
      • Richmond, Virginia, Estados Unidos, 23298
        • Virginia Commonwealth University Clinical Research Services Unit (CRSU)
      • Richmond, Virginia, Estados Unidos, 23226
        • Richmond Community Hospital LLC, Bon Secours Liver Institute of Richmond
    • Washington
      • Seattle, Washington, Estados Unidos, 98105
        • Liver Institute Northwest
  • França
      • Amiens, França, 80054
        • CHU Amiens Picardie
      • Créteil, França, 94000
        • Hôpital Henri Mondor
      • Grenoble, França, 38043
        • CHU Grenoble Alpes - Hôpital Albert Michallon
      • Orléans, França, 45067
        • Centre Hospitalier Régional d'Orléans
      • Paris, França, 75012
        • Hôpital Saint-Antoine
      • Paris, França, 75014
        • Hôpital Cochin
      • Paris, França, 75651
        • Hôpital Pitié-Salpétrière
      • Pessac, França, 33604
        • Hôpital Haut Lévêque
      • Reims, França, 51092
        • Hôpital Robert Debré - CHU de Reims
      • Strasbourg, França, 67200
        • Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
  • Itália
      • Bologna, Itália, 40138
        • Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
      • Milan, Itália, 20142
        • Azienda Ospedaliera San Paolo, Dipartimento di Scienza della Salute, UO Medicina VI e Pathologia e Gastroenterologia
      • Monza, Itália, 20900
        • ASST Monza - Ospedale San Gerardo, Gastroenterologia
      • Padova, Itália, 35128
        • Azienda Ospedale- Università degli Studi di Padova UOC Gastroenterologia
      • Palermo, Itália, 90127
        • Azienda Ospedaliera Universitaria Policlinico P. Giaccone, UOC di Gastroenterologia-Dip.Medicina Interna e Specialistica
    • Località Baggiovara
      • Modena, Località Baggiovara, Itália, 41126
        • Ospedale Civile di Baggiovara-Struttura Complessa di Medicina ad indririzzo Metabolico Nutrizionale
  • Reino Unido
      • Belfast, Reino Unido, BT12 6BA
        • Belfast Health and Social Care Trust-Royal Victoria Hospital
      • Camberley, Reino Unido, GU16 7UJ
        • Frimley Health NHS Foundation Trust - Frimley Park Hospital
      • Cambridge, Reino Unido, CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
      • Hull, Reino Unido, HU32J
        • Hull University Teaching Hospitals NHS Trust , Hull Royal Infirmary
      • London, Reino Unido, SE5 9RS
        • King's College Hospital. King's College NHS Foundation Trust
      • Nottingham, Reino Unido, NG72UH
        • Nottingham University Hospitals NHS Trust - Queen's Medical Centre (QMC)
      • Plymouth, Reino Unido, PL6 8DH
        • Plymouth Hospitals NHS Trust, Derriford Hospital
    • Newcastle
      • Newcastle upon Tyne, Newcastle, Reino Unido, NE7 7DN
        • The Newcastle upon Tyne Hospitals NHS Foundation Trust-Freeman Hospital
  • Suíça
      • Bern, Suíça, 3010
        • Inselspital, Universitätsspital Bern Universitätsklinik für Viszerale chirurgie und Medizin Hepatologie
      • Lugano, Suíça, 6900
        • Fondazione Epatocentro Ticino
  • Turquia (Türkiye)
      • Ankara, Turquia (Türkiye), 06230
        • Hacette Universitesi Hastenesi IC, Hastaliklari Anabilim Dali, Gastronenteroloji Bilim Dali, Mithapasa Cad. Hacettepe Mah.
    • Bornova
      • Izmir, Bornova, Turquia (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi Hastanesi
    • Pendik
      • Istanbul, Pendik, Turquia (Türkiye), 34890
        • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi, Gastroentoloji Bilim Dali
  • África do Sul
      • Cape Town, África do Sul, 7800
        • Mediclinic Constantiaberg, North Suites
    • Western Cap
      • Cape Town, Western Cap, África do Sul, 7925
        • Groote Schuur Hospital, University of Cape Town - Clinical Research Centre
    • Western Cape
      • Cape Town, Western Cape, África do Sul, 7530
        • Tiervlei Trial Centre

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria

  • Males or females age of 18 to 75 years (inclusive)
  • Definite or probable Primary biliary cholangitis (PBC) diagnosis
  • Alkaline phosphatase (ALP) ≥ 1.67x upper limit of normal (ULN)
  • Total bilirubin (TB) ≤ 2x ULN
  • Ursodeoxycholic acid (UDCA) for at least 12 months (stable dose ≥ 3 months) prior to screening, or unable to tolerate UDCA treatment (no UDCA for ≥ 3 months) prior to screening (per country standard-of-care dosing)
  • Must have PBC Worst Itch Numeric rating scale (NRS) collected prior to randomization
  • Females participating in this study must be of non-child bearing potential or must be using highly efficient contraception for the full duration of the study and for 1 month after the last drug intake

Exclusion Criteria:

  • History or presence of other concomitant liver disease
  • Clinically significant hepatic decompensation, including patients with complications of cirrhosis/portal hypertension
  • Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease) or which may diminish life expectancy to < 2 years, including known cancers
  • Patient has a positive test for HIV Type 1 or 2 at screening, or patient is known to have tested positive for HIV
  • Evidence of any other unstable or untreated clinically significant disease
  • History of alcohol abuse
  • For female patients: known pregnancy or lactating
  • Use of fibrates and glitazones within 2 months prior to screening
  • Use of Obeticholic acid (OCA), azathioprine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, budesonide and other systemic corticosteroids (parenteral and oral chronic administration only); potentially hepatotoxic drugs
  • (including α-methyl-dopa, sodium valproic acid isoniazid, or nitrofurantoin) within 3 months prior to screening
  • Use of antibodies or immunotherapy directed against interleukins (ILs) or other cytokines or chemokines within 12 months prior to screening
  • For patients with previous exposure to OCA, OCA should be discontinued 3 months prior to screening
  • Patients who are currently participating in, plan to participate in, or have participated in an investigational drug study or medical device study containing active substance within 30 days or five half-lives, whichever is longer, prior to screening; for patients with previous exposure to seladelpar, seladelpar should be discontinued 3 months prior to screening
  • Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) values > 5 x ULN
  • For patients with AT or TB>ULN at SV1, variability of AT or TB > 40% (see section 3.5.1)
  • Albumin<3.0 g/dl
  • Severely advanced patients according to Rotterdam criteria (TB > ULN and albumin <LLN)
  • INR > 1.3 due to altered hepatic function
  • CPK > 2 x ULN
  • Screening serum creatinine > 1.5 mg/dl
  • Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as patients with markers of kidney failure damage or eGFR < 60 mL/min/1.73 m^2) calculated by Modification of diet in renal disease (MDRD)
  • Platelet count < 150 x 10^3/μL
  • AFP > 20 ng/mL with 4-phase liver CT or MRI imaging suggesting presence of liver cancer
  • Known hypersensitivity to the investigational product or to any of the formulation excipients of the elafibranor or placebo tablet Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Elafibranor 80mg double-blind

Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning
Medicamento: Elafibranor 80mg

Elafibranor 80mg daily

Outros nomes:
  • Iqirvo®
Comparador de Placebo: Placebo

Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning
Medicamento: Placebo

Placebo daily
Experimental: Elafibranor 80mg open label

Study participants will take 1 tablet per day orally before breakfast with a glass of water each morning
Medicamento: Elafibranor 80mg

Elafibranor 80mg daily

Outros nomes:
  • Iqirvo®

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants With Response to Treatment Based on Cholestasis Response at Week 52
Prazo: At Week 52

Cholestasis response was defined as alkaline phosphatase (ALP) < 1.67 x upper limit of normal (ULN) and total bilirubin (TB) <= ULN and ALP decrease from baseline >= 15% at Week 52 and based on the composite strategy imputing non-response for participants who experienced intercurrent events (ICEs) (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
At Week 52

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Key Secondary Endpoint: Percentage of Participants With Response to Treatment Based on ALP Normalization at Week 52
Prazo: At Week 52

Response to treatment based on normalization of ALP at Week 52 was defined as percentage of participants with ALP =<1.0× ULN and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
At Week 52
Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch Numeric Rating Scale (NRS) Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 52
Prazo: Baseline (up to 14 days pre-dose) and Week 52

The PBC Worst Itch NRS is a simple, self-administered patient reported outcome (PRO) questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).
Baseline (up to 14 days pre-dose) and Week 52
Key Secondary Endpoint: Change From Baseline in Pruritus Based on PBC Worst Itch NRS Score in Participants With Baseline PBC Worst Itch NRS Score ≥4 to Week 24
Prazo: Baseline (up to 14 days pre-dose) and Week 24

The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).
Baseline (up to 14 days pre-dose) and Week 24
Change From Baseline in ALP at Weeks 4, 13, 26, 39 and 52
Prazo: Baseline (Day 1) and at Weeks 4, 13, 26, 39 and 52

Blood samples were collected at specified timepoints for assessment of ALP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Weeks 4, 13, 26, 39 and 52
Percentage of Participants With ALP Response From Baseline at Week 52
Prazo: Baseline (Day 1) and at Week 52

ALP response was defined as ALP decrease from baseline >= 10%; ALP decrease from baseline >= 20% and ALP decrease from baseline >= 40% at Week 52 and based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Percentage of Participants With Response to Treatment According to ALP < 1.5x ULN, ALP Decrease From Baseline >= 40% and TB =<ULN at Week 52
Prazo: At Week 52

Response to treatment was according to ALP < 1.5x ULN, ALP decrease from baseline >= 40% and TB =<ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
At Week 52
Percentage of Participants With Response to Treatment According to ALP < 3x ULN, Aspartate Aminotransferase (AST) < 2x ULN and TB =< 1 Milligrams Per Deciliter (mg/dL) (Paris I) at Week 52
Prazo: At Week 52

Response to treatment was according to ALP < 3x ULN, AST < 2x ULN and TB =< 1 mg/dL (Paris I) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
At Week 52
Percentage of Participants With Response to Treatment According to ALP =< 1.5x ULN, AST =< 1.5x ULN and TB =< 1 mg/dL (Paris II) at Week 52
Prazo: At Week 52

Response to treatment was according to ALP =< 1.5x ULN, AST =< 1.5x ULN and TB =< 1 mg/dL (Paris II) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
At Week 52
Percentage of Participants With Response to Treatment According to TB Decrease of 15% Change From Baseline at Week 52
Prazo: At Week 52

Response to treatment was according to TB decrease of 15% change from baseline at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
At Week 52
Percentage of Participants With Response to Treatment According to Normalization of TB (TB =< ULN) and/or Albumin (ALB >= Lower Limit of Normal [LLN]) (Rotterdam) at Week 52
Prazo: At Week 52

Response to treatment was according to TB (TB =< ULN) and/or albumin (ALB >= LLN) (Rotterdam) at week 52. Participant was considered as responder at Week 52 only if total bilirubin and albumin were normal. The endpoint was analyzed in participants with abnormal total bilirubin (TB > ULN) or albumin (ALB < LLN) at baseline. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
At Week 52
Percentage of Participants With Response to Treatment According to TB ≤0.6 x ULN at Week 52
Prazo: At Week 52

Response to treatment was according to TB ≤0.6 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
At Week 52
Percentage of Participants With Response to Treatment According to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52
Prazo: At Week 52

Response to treatment was according to ALP ≤1.67 x ULN and TB ≤1 mg/dL (Momah/ Lindor) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
At Week 52
Percentage of Participants With Response to Treatment According to no Worsening of TB at Week 52
Prazo: At Week 52

Response to treatment was according to no worsening of TB, which was defined as level of TB <ULN or no increase from baseline of more than 0.1 x ULN at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
At Week 52
Percentage of Participants With Response to Treatment According to Complete Biochemical Response at Week 52
Prazo: At Week 52

Response to treatment according to complete biochemical response which was defined as <= ULN values of ALP, TB, AST, ALT and ALB, and international normalized ratio (INR) at Week 52. It was based on the composite strategy imputing non-response for participants who experienced ICEs (study treatment discontinuation or use of rescue therapy for PBC) prior to Week 52.
At Week 52
PBC 5-, 10- and 15-year Risk Scores Based on United Kingdom (UK)-PBC Score at Week 52
Prazo: At Week 52

The UK-PBC risk score was defined by the mean percentage risk that a PBC participant treated with UDCA would develop liver failure requiring liver transplantation in 5, 10, and 15 years from diagnosis. It is calculated from the following equation at week 52 as follows: UK-PBC score = 0.0287854*(alpEPxULN-1.722136304) - 0.0422873*([{altastEP x ULN/10}^-1] - 8.675729006) + 1.4199 * (LN(bilEPxULN /10)+2.709607778) - 1.960303*(alb x LLN -1.17673001)-0.4161954*(plt x LLN -1.873564875). The survival S(t) for any given participants was then calculated by S(t) = S0(t) exp(UK-PBC score). Here, alpEP x ULN=ALP /Upper Level Normal ALP at the timepoint, altastEPxULN=(ALT, AST or TA) /upper level normal of the value at the timepoint, bilEP x ULN=bilirubin /upper level normal bilirubin at the timepoint, alb x LLN=alb /alb lower level normal at baseline and plt x LLN=plt/plt lower level normal at baseline. Lower UK-PBC score predicts lower risk and better prognosis.
At Week 52
Global PBC Study Group (GLOBE) Score at Week 52
Prazo: At Week 52

The GLOBE score was a validated risk assessment tool providing an estimate of transplant-free survival for participants with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 participants with PBC. It is calculated from the following equation at week 52 as follows: GLOBE score = 0.044378 * age at start of ursodeoxycholic acid (UDCA) therapy + 0.93982 * LN (TB x ULN) + 0.335648 * LN (ALP x ULN) - 2.266708 * ALB x LLN - 0.002581 * platelet count per 10^9/L) + 1.216865; where TB x ULN = bilirubin/ULN at the timepoint, ALP x ULN = ALP/ULN at the timepoint, ALB x LLN = ALB/LLN at the timepoint, platelet count per 10^9/L = platelet count per 10^9/L at the timepoint. The Lower GLOBE PBC score predicts lower risk and better prognosis.
At Week 52
Change From Baseline in Hepatobiliary Injury and Liver Function as Assessed by AST, ALT, Gamma-glutamyl Transferase (GGT), 5 Prime Nucleotidase (5'-NT), and Fractionated ALP (Hepatic) (H1 and H2) at Week 52
Prazo: Baseline (Day 1) and at Week 52

Hepatobiliary injury and liver function were assessed as measured by AST, ALT, GGT, 5'-NT, and fractionated ALP (hepatic) (H1 and H2). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Total and Conjugated Bilirubin at Week 52
Prazo: Baseline (Day 1) and at Week 52

Hepatobiliary injury and liver function were assessed as measured by total and conjugated bilirubin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by Albumin at Week 52
Prazo: Baseline (Day 1) and at Week 52

Hepatobiliary injury and liver function were assessed as measured by albumin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Hepatobiliary Injury and Liver Function as Measured by INR at Week 52
Prazo: Baseline (Day 1) and at Week 52

Hepatobiliary injury and liver function were assessed as measured by INR. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers of Inflammation as Measured by High-sensitivity C-reactive Protein (hsCRP) at Week 52
Prazo: Baseline (Day 1) and at Week 52

Biomarkers of inflammation were assessed as measured by hsCRP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers of Inflammation as Measured by Fibrinogen and Haptoglobin at Week 52
Prazo: Baseline (Day 1) and at Week 52

Biomarkers of inflammation were assessed as measured by fibrinogen and haptoglobin. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers of Inflammation as Measured by Tumor Necrosis Factor Alpha at Week 52
Prazo: Baseline (Day 1) and at Week 52

Biomarkers of inflammation were assessed as measured by TNF-alpha. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Immune Response as Measured by Immunoglobulin (Ig)G and IgM at Week 52
Prazo: Baseline (Day 1) and at Week 52

Immune response was assessed as measured by IgG and IgM. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Enhanced Liver Fibrosis (ELF) and Plasminogen Activator Inhibitor-1 (PAI-1) at Week 52
Prazo: Baseline (Day 1) and at Week 52

Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by ELF: hyaluronic acid [HA], type 2 procollagen peptide [PIINP], tissue inhibitor of metalloproteinases-1[TIMP-1]) and PAI-1. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Cytokeratin-18 (CK-18) at Week 52
Prazo: Baseline (Day 1) and at Week 52

Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by CK-18 (M30 and M65). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Biomarkers and Non-invasive Measures of Hepatic Fibrosis as Measured by Transforming Growth Factor Beta (TGF-beta) at Week 52
Prazo: Baseline (Day 1) and at Week 52

Biomarkers and non-invasive measures of hepatic fibrosis were assessed as measured by TGF-beta. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Liver Stiffness Measured by Transient Elastography (TE) at Week 52
Prazo: Baseline (Day 1) and at Week 52

FibroScan® TE device (Echosens, Paris, France) is a non-invasive technique used to measure liver stiffness, which correlated with fibrosis. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Lipid Parameters at Week 52
Prazo: Baseline (Day 1) and at Week 52

Blood samples were collected at specified timepoints for assessment of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol and triglycerides (TG). Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52
Prazo: Baseline (Day 1) and at Week 52

Blood samples were collected at specified timepoints for assessment of FPG. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis at Week 52
Prazo: Baseline (Day 1) and at Week 52

Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline at Week 52 in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured by 7 Alpha-hydroxy-4-cholesten-3-one (C4) at Week 52
Prazo: Baseline (Day 1) and at Week 52

Blood samples were collected at specified timepoints for assessment of bile acids and biomarkers of bile acid synthesis as measured by C4. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Bile Acids and Biomarkers of Bile Acid Synthesis as Measured Fibroblast Growth Factor 19 at Week 52
Prazo: Baseline (Day 1) and at Week 52

Blood samples were collected at specified timepoints for assessment bile acids and biomarkers of bile acid synthesis as measured by Fibroblast Growth Factor 19. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Percentage of Participants With Response in PBC Worst Itch NRS Score at Weeks 24 and 52
Prazo: Baseline (up to 14 days pre-dose) and at Week 24 and Week 52

The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Response to PBC Worst Itch NRS was according to clinically meaningful change at least 30% reduction; one point, two points or three points decrease in score from baseline in participants with a baseline NRS score ≥4. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake).
Baseline (up to 14 days pre-dose) and at Week 24 and Week 52
Percentage of Participants With no Worsening of Pruritus as Measured by the PBC Worst Itch NRS Score at Weeks 24 and 52
Prazo: Baseline (up to 14 days pre-dose) and at Week 24 and Week 54

The PBC Worst Itch NRS is a simple, self-administered PRO questionnaire that measures itch intensity. Participants rate intensity of their worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Total score ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse outcomes. Baseline was defined as the average of the daily PBC Worst itch scores on available data within 14 days prior the day of randomization. Post-baseline data was defined as the average of the daily PBC Worst itch scores on available data in 4-week period intervals (available data every 28 days after the day of first study drug intake). A worsening of Pruritus was defined by a positive change from baseline in PBC Worst Itch NRS score greater than 2 at week 24 and 52.
Baseline (up to 14 days pre-dose) and at Week 24 and Week 54
Change From Baseline in 5-D Itch at Week 52
Prazo: Baseline (Day 1) and at Week 52

The 5-D Itch scale is a questionnaire that has been validated in several different diseases. It assesses symptoms in terms of 5 domains: duration: score range 1 (less than 6 hours) to 5 (all day); degree: score range 1 (not present) to 5 (unbearable); duration: score range 1 (less than 6 hours) and 5 (all day); direction: score range 1(completely resolved) and 5 (getting worse); disability: score range 1 (never affects or not applicable) and 5 (delays falling asleep and frequently wakes up at night or always affects this activity) and distribution: where the question was to mark where itching is present in body parts over the last two weeks. Participants rated their symptoms over preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. The 5-D Itch total score ranged between 5 (no pruritus) and 25 (most severe pruritus). Higher scores indicated worse outcomes. Baseline= last non-missing value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a at Week 52
Prazo: Baseline (Day 1) and at Week 52

The PROMIS Fatigue Short Form 7a consists of seven items that measure both the experience of fatigue and the interference of fatigue on daily activities over the past week. Participants completed the PROMIS Fatigue Short Form 7a and answered following questions on a scale from 1 (never) to 5 (always) : "How often did you feel tired"; "How often did you experience extreme exhaustion"; "How often did you run out of energy"; "How often did your fatigue limit you at work"; "How often were you too tired to think clearly"; "How often were you too tired to take a bath or shower" and 'How often did you have enough energy to exercise strenuously". T-score values include mean of 50 and standard deviation of 10. The PROMIS Fatigue T-score ranged from 29.4 (best) to 83.2 (worst). Higher scores indicated worse outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Epworth Sleepiness Scale (ESS) at Week 52
Prazo: Baseline (Day 1) and at Week 52

The ESS is a short, self-administered questionnaire that consists of 8 questions asking to rate how likely it is to fall asleep in everyday situations (each question can be scored from 0 to 3 points; '0' indicates no chance of dozing and '3' indicates high chance of dozing). It provides a total score which has been shown to relate to the participant's level of daytime sleepiness (total score range 0 [no sleepiness] to 24 points [significant sleepiness]). The total score is the sum of all item scores and ranged from 0 (best) to 24 (worst). Higher scores indicated more chances of sleepiness. Participants were asked to complete the ESS with regard to the level of sleepiness they experienced over approximately the past 7 days. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in PBC-40 at Week 52
Prazo: Baseline (Day 1) and at Week 52

PBC-40 assess symptoms across 6 domains:symptoms,itch,fatigue,cognitive,emotional and social. Participants responded on verbal response scale,depending on section options range from 'never'/'not at all'/'strongly disagree' to 'always'/'very much'/'strongly agree'.5 items (3/3 in itch domain and 2/10 in social domain)also included a 'does not apply' option.Domains:Symptoms(7 questions)score range 7-35,Itch(3 questions)score range 3-15,Fatigue(11 questions)score range 11-55,Cognitive(6 questions)score range 6-30,Emotional(3 questions)score range 3-15,Social(10 questions)score range 10-50.Score for each domain was provided(total score was not calculated),with each verbal response scale correlating to score of 1-5 per item(0-5 on items with a 'does not apply' option);5=most affected.Individual item scores are summed to give total domain score.Higher scores=worse outcomes.PBC-40 had 4-week recall period.Baseline=last non-missing value on or before first dose of randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Health Utility as Measured by the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) at Week 52
Prazo: Baseline (Day 1) and at Week 52

The EQ-5D-5L is a 6-item, standardized questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health state. The visual analog scale (VAS) of EQ-5D-5L questionnaire is numbered from 0 (worst) to 100 (best). Higher scores indicated better outcomes. Baseline was defined as the last non-missing value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in T-Scores for Bone Mineral Density Assessed by Dual-energy X-ray Absorptiometry (DEXA) Scanning at Week 52
Prazo: Baseline (Day 1) and at Week 52

DEXA scanning (hip and lumbar) was performed in participants to assess bone mineral density (femoral neck, lumbar and total hip). T-scores were calculated based on actual measured bone density value. The T-score compared a participant's bone density against that of a healthy 30-year-old adult. T-scores were used to determine primary osteoporosis, which exists on its own without any other cause and were divided into 3 categories: low risk, medium risk, and high risk (osteoporosis). T-scores measure the number of minerals in a participant's bone. A participant's level of bone loss was compared to that of a typical, healthy 30-year-old adult. A score ≥-1.0 indicates low risk, medium risk is a score between-2.5 and -1.0, and a high risk/osteoporosis is a score ≤-2.5. A positive change in T-score indicates an improvement in bone mineral density. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Serum Markers of Bone Turnover Carboxy Terminal Crosslinked Telopeptides of Type 1 Collagen [CTX] at Week 52
Prazo: Baseline (Day 1) and at Week 52

Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, CTX. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Change From Baseline in Serum Markers of Bone Turnover Type 1 Procollagen Peptide [P1NP]) at Week 52
Prazo: Baseline (Day 1) and at Week 52

Blood samples were collected at specified timepoints for assessment of serum markers of bone turnover, P1NP. Baseline was defined as the last non-missing central value on or before the first dose of the randomized study medication.
Baseline (Day 1) and at Week 52
Percentage of Participants With Onset of Clinical Outcomes
Prazo: From Day 1 up to Week 52

Onset of clinical outcomes were described as a composite endpoint composed of the following: model for end stage liver disease sodium (MELD-Na) >14 for participants with baseline MELD-Na <12; liver transplant; uncontrolled ascites requiring treatment; hospitalization for new onset or recurrence of any including, variceal bleed, hepatic encephalopathy defined as West-Haven score of 2 or more and spontaneous bacterial peritonitis; and death.
From Day 1 up to Week 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs)
Prazo: TEAEs were collected from the start of study treatment administration (Day 1) up to DCO date of 01 June 2023, approximately 980 days.

An AE was any untoward medical occurrence in a participant or clinical investigation participant who was administered an investigational product, and which does not necessarily have a causal relationship with treatment. A TEAE was defined as any AE with onset during TEAE assessment period, or any event started prior to first dose of treatment and worsened or became serious during the TEAE assessment period. An SAE was any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect. An AESI was an AE that might not be serious but was of special importance to a particular treatment or class.
TEAEs were collected from the start of study treatment administration (Day 1) up to DCO date of 01 June 2023, approximately 980 days.
Plasma Concentrations of Elafibranor and GFT1007
Prazo: Week 4: pre-dose, 0.5 hour, 1.5 hours, between 2-3 hours, 4 hours and 6 hours post-dose

Blood samples were collected at specified timepoints to evaluate plasma concentration of Elafibranor and its metabolite GFT1007.
Week 4: pre-dose, 0.5 hour, 1.5 hours, between 2-3 hours, 4 hours and 6 hours post-dose

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Ipsen

Investigadores

  • Diretor de estudo: Ipsen Medical Director, Ipsen

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

24 de setembro de 2020

Conclusão Primária (Real)

1 de junho de 2023

Conclusão do estudo (Estimado)

1 de dezembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

21 de agosto de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

21 de agosto de 2020

Primeira postagem (Real)

26 de agosto de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

20 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • GFT505B-319-1
  • 2019-004941-34 (Número EudraCT)
  • 2019 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Prazo de Compartilhamento de IPD

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Critérios de acesso de compartilhamento IPD

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever